Liu Luyao, Huang Hai, Cheng Bin, Xie Huaping, Peng Wang, Cui Haochen, Liang Jingwen, Cao Mengdie, Yang Yilei, Chen Wei, Wang Ronghua, Zhao Yuchong
Department of Gastroenterology and Hepatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
iScience. 2024 Dec 16;28(1):111612. doi: 10.1016/j.isci.2024.111612. eCollection 2025 Jan 17.
Cancer-associated fibroblasts (CAFs) represent a major contributor to tumor growth. Cellular senescence is a state of cell-cycle arrest characterized by a pro-inflammatory phenotype. The potential impact of CAF senescence on tumor progression and the tumor microenvironment (TME) remains to be elucidated. Here, we systematically investigated the relationship between CAF senescence and the TME of pancreatic ductal adenocarcinoma (PDAC) based on multi-omics analysis and functional experiments. CAF senescence promotes tumor progression and and contributes to the formation of immunosuppressive TME. A CAF-senescence-related risk score was developed to predict overall survival, immune landscape, and treatment sensitivity in patients with PDAC. Further experiments revealed that plasminogen activator urokinase (PLAU) derived from senescent CAFs (SCAFs) promoted PDAC progression and was involved in immunosuppression. Together, these findings suggested that CAF senescence was correlated with tumor progression, and the CAF-senescence-based machine learning model could potentially predict prognosis in patients with PDAC.
癌症相关成纤维细胞(CAFs)是肿瘤生长的主要促成因素。细胞衰老是以促炎表型为特征的细胞周期停滞状态。CAF衰老对肿瘤进展和肿瘤微环境(TME)的潜在影响仍有待阐明。在此,我们基于多组学分析和功能实验,系统地研究了CAF衰老与胰腺导管腺癌(PDAC)肿瘤微环境之间的关系。CAF衰老促进肿瘤进展,并有助于免疫抑制性肿瘤微环境的形成。开发了一种与CAF衰老相关的风险评分,以预测PDAC患者的总生存期、免疫格局和治疗敏感性。进一步的实验表明,源自衰老CAF(SCAFs)的纤溶酶原激活物尿激酶(PLAU)促进了PDAC的进展,并参与了免疫抑制。总之,这些发现表明CAF衰老与肿瘤进展相关,基于CAF衰老的机器学习模型可能预测PDAC患者的预后。